Trials / Completed
CompletedNCT05625412
A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to assess the safety and tolerability of BMS-986360 as monotherapy and in combination with chemotherapy or nivolumab in participants with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986360 | Specified dose on specified days |
| DRUG | Docetaxel | Specified dose on specified days |
| DRUG | Nivolumab | Specified dose on specified days |
| DRUG | Capecitabine | Specified dose on specified days |
Timeline
- Start date
- 2022-12-09
- Primary completion
- 2025-05-12
- Completion
- 2025-05-12
- First posted
- 2022-11-22
- Last updated
- 2025-06-13
Locations
35 sites across 9 countries: United States, Argentina, Australia, Canada, Chile, France, Italy, Mexico, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05625412. Inclusion in this directory is not an endorsement.